Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Makaleler > Tam Makale · 2016
Yazarlar: Abdullah SAYINER, Jadwiga A. Wedzicha, Donald Banerji, Kenneth R. Chapman, Jorgen Vestbo, Nicolas Roche, Timothy Ayers, Chau Thach, Robert Fogel, Francesco Patalano, Claus F. Vogelmeier
NEW ENGLAND JOURNAL OF MEDICINE, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2016, cilt 374, ss 2222-2234
Özet
BACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.